Children with premature pubarche: is an alterated neonatal 17-Ohp screening test a predictive factor?

Ital J Pediatr. 2018 Jan 16;44(1):10. doi: 10.1186/s13052-018-0444-6.

Abstract

Background: Neonatal screening for 21 hydroxylase deficiency is designed to detect classical form of congenital adrenal hyperplasia (CAH). It is still unclear whether newborns who result false positives at neonatal screening might later develop signs of androgen excess. The aim of this study is to verify whether a slightly elevated 17-OHP at newborn screening is a predictive factor for premature pubarche.

Methods: We evaluated all infants born between 2001 and 2014 with premature pubarche. In case of increased bone age, they were submitted to functional tests to find out the cause of their symptoms. Their 17-OHP values at newborn screening for CAH were reconsidered.

Results: We identified 330 patients (269 females, 61 males) with premature pubarche. All these children had a normal 17-OHP at newborn screening with the exception of a child, born preterm and not affected by CAH.

Conclusions: An elevated 17-OHP at newborn screening is not a predictive factor for premature pubarche. A likely cause of increased 17-OHP level at screening is an immaturity of adrenal gland or a neonatal stress. Therefore a strict follow up of these neonates during childhood is not necessary.

Keywords: 17-Ohp; Congenital adrenal hyperplasia; Newborn screening; Premature pubarche.

MeSH terms

  • Adrenal Hyperplasia, Congenital / diagnosis*
  • Adrenal Hyperplasia, Congenital / epidemiology
  • Age Factors
  • Cohort Studies
  • Female
  • Humans
  • Incidence
  • Infant, Newborn
  • Male
  • Neonatal Screening / methods*
  • Predictive Value of Tests
  • Puberty, Precocious / diagnosis*
  • Puberty, Precocious / epidemiology
  • Retrospective Studies
  • Risk Assessment
  • Sex Factors

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency